Asia
The medtech titan was told to make a public apology and remove the content.
The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation.
According to a SEC filing, the cost of the facility will be paid in part by the State of New York.
Shanghai Fosun Pharma announced a $50M U.S. joint venture, a JV that includes two Fosun entities.
The portfolio consists of acute, chronic and oncology products.
Teva has made a target of cutting costs by $3B by the end of 2019.
Fosun Pharma acquired China rights to market a novel treatment for Parkinson’s disease from Bial in an $18M agreement. BIAL developed Ongentys as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors.
3SBio reported the CFDA formally approved Bydureon, its once-weekly Glucagon-like peptide-1 receptor agonist for type 2 diabetes treatment.
Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine.
East Sunshine Foresight Fund will make a “series of investments” of unspecified size in Enlyton, a Columbus, Ohio company developing novel imaging contrast agents.
PRESS RELEASES